Skip to main content

Table 5 End-of-treatment and sustained virologic response rates in patients treated to week 48

From: The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil

End-of-treatment response Patients treated n = 216, n (%) p*
End-of-treatment Response at week 48, n (%) 140/216 (64.8%)  
Non-responder to initial treatment 81/128(63.3%) 0.671
Relapsed to initial treatment 59/88 (67%)  
Sustained Virologic Response at week 72, n (%) 88/216 (40.7%)  
Non-responder to initial treatment 44/128 (34.4%) 0.031
Relapsed to initial treatment 44/88 (50%)  
  1. * Significance based on Fisher’s Exact test.